Look no further than our top two stories of the year, and you’ll see that the GLP-1 craze and Big Pharma layoffs took center ...

Madrigal Pharmaceuticals, X4 Pharmaceuticals and Day One Biopharmaceuticals secured their maiden approvals this year in metabolic dysfunction-associated steatohepatitis, WHIM syndrome and pediatric ...

2. Madrigal’s Rezdiffra (resmetirom) for NASH/MASH Madrigal is turning biotech heads with its launch of NASH drug Rezdiffra, which notched an FDA approval March 14 as the first treatment for the liver ...

Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.

For those dealing with fatty liver disease, there’s welcome news to report. Earlier this year, the United States Food and ...

The FDA approved the first treatment for nonalcoholic steatohepatitis (NASH) on March 14: Madrigal Pharmaceuticals’ Rezdiffra, or resmetirom. NASH is characterized by the buildup of fatty tissue in ...

Wake up with Breakfast news in your inbox every market day. Sign Up For Free » When it was approved in March 2024, Rezdiffra became the only medicine approved by the Food and Drug Administration ...

No drugs are approved specifically to treat MASLD. One drug, resmetirom (Rezdiffra), is approved to treat the advanced stage of the condition, called metabolic dysfunction-associated liver disease ...